Research, Medical

Small Molecule Apis Made with Compelling Science

July 17, 2023

Small Molecule Apis Made
As your API demand grows, we grow with you. While we can manufacture volumes in metric tons, we can also go small. If you have a chemistry-based compound and need smaller batches for clinical or commercial use, we can offer the quantities you need at our cGMP small-scale/pilot facilities until you’re ready for full-scale manufacturing.

Spotlight

Axela

At Axela, we create tools and content to simplify multiplex biomarker detection for translational research and diagnostic testing. Our systems are built upon advanced flow-through technologies that enable rapid, real time multiplex immunoassays as well as high performance nucleic acid and protein microarray analysis.

OTHER WHITEPAPERS
news image

Eliminate Noisy Oxygen Measurements in Bioreactors

whitePaper | March 27, 2023

Controlling the dissolved oxygen level in fermentation vessels and bioreactors is vital to maximizing production yield and ensuring high end-product quality.

Read More
news image

The A to Z of microarrays evolution of a revolutionary solution

whitePaper | May 27, 2023

The Human Genome Project was a monumental effort over more than a decade to determine the human DNA sequence and analyze genetic variation among individuals. The hope was that, armed with this understanding, phenotypic differences would be explainable by genetic variation, and health benefits could follow.

Read More
news image

Are Nitrosamines aConcern for BiologicManufacturers?

whitePaper | July 12, 2023

The discovery of nitrosamine genotoxins in several pharmaceuticals has led to monitoring and re-evaluation of manufacturing practices for those products considered atrisk. This article provides an assessment of nitrosamine contamination specifically in biologics and contrasts the potential risks between these product types.

Read More
news image

Validation of ICON™ Automated Cell Counting and Viability Assay

whitePaper | August 10, 2022

Determination of cell viability and concentration using trypan blue exclusion is essential for biotherapeutic workflows, enabling optimisation of protocols, monitoring of changes to the culture environment, and selection of the best clones for culture progression.

Read More
news image

Accelerating Global Access to Gene Therapies: Case Studies from Lowand Middle-Income Countries

whitePaper | October 18, 2022

This document is published by the World Economic Forum as a contribution to a project, insight area or interaction. The findings, interpretations and conclusions expressed herein are a result

Read More
news image

Viral Vectors as a Gene Delivery Vehicle

whitePaper | August 5, 2022

The field of gene and cell therapy is experiencing a renaissance, with innovations in the use of viral vectors as a gene delivery vehicle being a key factor in the field’s growth.

Read More

Spotlight

Axela

At Axela, we create tools and content to simplify multiplex biomarker detection for translational research and diagnostic testing. Our systems are built upon advanced flow-through technologies that enable rapid, real time multiplex immunoassays as well as high performance nucleic acid and protein microarray analysis.

Events